UOC
CNTB

UBS O'Connor’s Connect Biopharma Holdings CNTB Stock Holding History

UBS O'Connor’s Portfolio CNTB Stock Details CNTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-268,946
Closed -$148K – 397
2025
Q1 		$148K Sell
268,946
-241,755
-47% -$224K ﹤0.01% 257
2024
Q4 		$705K Hold
510,701
– – 0.02% 259
2024
Q3 		$725K Hold
510,701
– – 0.02% 310
2024
Q2 		$776K Hold
510,701
– – 0.02% 329
2024
Q1 		$889K Sell
510,701
-50,490
-9% -$61.4K 0.03% 287
2023
Q4 		$662K Sell
561,191
-42,709
-7% -$50.7K 0.02% 321
2023
Q3 		$469K Hold
603,900
– – 0.01% 406
2023
Q2 		$670K Buy
603,900
+29,752
+5% +$33.4K 0.01% 422
2023
Q1 		$574K Buy
+574,148
New +$626K 0.01% 455
2022
Q4 		– Sell
-613,931
Closed -$792K – 70
2022
Q3 		$792K Sell
613,931
-37,575
-6% -$45.1K 0.01% 766
2022
Q2 		$567K Buy
+651,506
New +$959K 0.01% 807

Other funds holding CNTB

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
CL
Choreo LLC Rockford, Illinois $8.15B AUM 20.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KWM
Koa Wealth Management Encinitas, California $138M AUM 13.03% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

UBS O'Connor's CNTB Position: Q2 2025 in Review

UBS O'Connor sold out of Connect Biopharma Holdings (CNTB) in Q2 2025, closing a stake of 268,946 shares — an estimated $148K sold.

UBS O'Connor first reported a position in CNTB in Q2 2022 and held it in 11 quarters. The position peaked at $889K in Q1 2024. 17 funds tracked by Wall St. Rank hold CNTB as of Q2 2025.

  • UBS O'Connor reported no remaining Connect Biopharma Holdings position as of Q2 2025 after selling out during the quarter.
  • UBS O'Connor sold 268,946 Connect Biopharma Holdings shares in Q2 2025, an estimated $148K.
  • UBS O'Connor first reported a position in Connect Biopharma Holdings in Q2 2022 and held it in 11 quarters.
  • UBS O'Connor's Connect Biopharma Holdings position peaked at $889K in Q1 2024.
  • 17 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q2 2025.

Based on UBS O'Connor's 13F filing for Q2 2025, filed 14 Aug 2025.